All In Biotech

Free tool

FAERS Monitor: Tryptyr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217370 or its brand name (Tryptyr, Acoltremon). Reports on generic versions are filed under their own applications.

Reports

6,335

Serious

166

3% of reports

Hospitalization

49

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation3,268
  • drug ineffective1,382
  • eye pain1,110
  • dry eye604
  • vision blurred511
  • ocular hyperaemia489
  • lacrimation increased280
  • ocular discomfort260
  • eye pruritus203
  • condition aggravated190
  • headache186
  • visual impairment143
  • eye swelling133
  • inappropriate schedule of product administration102
  • drug hypersensitivity98

Reports by year received

View as table
YearReports
20241
20251,312
20265,022

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,824 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye irritationSignal3,268199.8194.8611,195
ocular discomfortSignal26078.769.719,414
eye painSignal1,11066.663.170,447
dry eyeSignal60440.737.723,095
ocular hyperaemiaSignal48934.631.715,772
lacrimation increasedSignal28031.027.78,048
eye pruritusSignal20320.217.63,664
vision blurredSignal51112.411.45,358
eye swellingSignal13311.910.11,316
visual impairmentSignal1433.83.3298
drug ineffectiveSignal1,3823.53.32,606
condition aggravatedSignal1902.11.8106
inappropriate schedule of product administration1021.91.641
drug hypersensitivity981.71.427
headache1861.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.